FDA Roundup: First-Line Hernexeos, Weekly Yuviwel, Expanded Palynziq & Sogroya Indications

The FDA handed out a string of approvals in late February and early March, granting regulatory clearances across several therapeutic areas - from oncology and rare genetic disorders to growth deficiencies.Let's take a look at the treatments that recently secured the regulatory nod.Boehringer Ingelheim Pharmaceuticals Inc. On February 26, 2026, the FDA granted accelerated approval to Boehringer Ingelheim's Hernexeos as a first-line treatment for adult patients with advanced non-small cell lung cancer (NSCLC ...